Urine VCAM-1 as a marker of renal pathology activity index in lupus nephritis

Arthritis Research and Therapy

Volumn 14, Issue 4, 2012, Pages

  Singh, Sandeep ^a   Wu, Tianfu ^a   Xie, Chun ^a   Vanarsa, Kamala ^a   Han, Jie ^a   Mahajan, Tina ^a   Oei, Ho B ^a   Ahn, Chul ^a   Zhou, Xin J ^a   Putterman, Chaim ^b   Saxena, Ramesh ^a   Mohan, Chandra ^a  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^b ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CREATININE; CXCL16 CHEMOKINE; MONOCYTE CHEMOTACTIC PROTEIN 1; NEUTROPHIL CYTOPLASMIC ANTIBODY; VASCULAR CELL ADHESION MOLECULE 1; BIOLOGICAL MARKER;

ADULT; AREA UNDER THE CURVE; ARTICLE; CELL INFILTRATION; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DISEASE ACTIVITY; DISEASE ASSOCIATION; DISEASE SEVERITY; FEMALE; FOCAL GLOMERULOSCLEROSIS; HUMAN; KIDNEY BIOPSY; KIDNEY DISEASE; LONGITUDINAL STUDY; LUPUS ERYTHEMATOSUS NEPHRITIS; MAJOR CLINICAL STUDY; MALE; MEMBRANOUS GLOMERULONEPHRITIS; MINIMAL CHANGE GLOMERULONEPHRITIS; PREDICTIVE VALUE; PROTEIN EXPRESSION; PROTEIN URINE LEVEL; URINALYSIS; FOLLOW UP; KIDNEY; LUPUS NEPHRITIS; METABOLISM; PATHOLOGY; URINE;

ADULT; BIOMARKERS; FEMALE; FOLLOW-UP STUDIES; HUMANS; KIDNEY; LUPUS NEPHRITIS; MALE; VASCULAR CELL ADHESION MOLECULE-1;

EID: 84864509775     PISSN: 14786354     EISSN: 14786362     Source Type: Journal    
DOI: 10.1186/ar3912     Document Type: Article

References (37)

1. Appel GRJ, D'Agati V. The Kidney 2007, Philadelphia, PA: Saunders Elsevier, 8.
2. US Renal Data System Incidence of reported ESRD, by primary diagnosis. 2002-2006 Combined 2008, US Renal Data System.
3. Fiehn C, Hajjar Y, Mueller K, Waldherr R, Ho AD, Andrassy K. Improved clinical outcome of lupus nephritis during the past decade: importance of early diagnosis and treatment. Ann Rheum Dis 2003, 62:435-439. 10.1136/ard.62.5.435, 1754523, 12695156.
4. Faurschou M, Starklint H, Halberg P, Jacobsen S. Prognostic factors in lupus nephritis: diagnostic and therapeutic delay increases the risk of terminal renal failure. J Rheumatol 2006, 33:1563-1569.
5. Esdaile JM, Joseph L, MacKenzie T, Kashgarian M, Hayslett JP. The benefit of early treatment with immunosuppressive agents in lupus nephritis. J Rheumatol 1994, 21:2046-2051.
6. Rovin BH, Song H, Birmingham DJ, Hebert LA, Yu CY, Nagaraja HN. Urine chemokines as biomarkers of human systemic lupus erythematosus activity. J Am Soc Nephrol 2005, 16:467-473. 10.1681/ASN.2004080658, 15601744.
7. Li Y, Tucci M, Narain S, Barnes EV, Sobel ES, Segal MS, Richards HB. Urinary biomarkers in lupus nephritis. Autoimmun Rev 2006, 5:383-388. 10.1016/j.autrev.2005.10.006, 16890891.
8. Enghard P, Riemekasten G. Immunology and the diagnosis of lupus nephritis. Lupus 2009, 18:287-290. 10.1177/0961203308099632, 19276295.
9. Wu T, Xie C, Wang HW, Zhou XJ, Schwartz N, Calixto S, Mackay M, Aranow C, Putterman C, Mohan C. Elevated urinary VCAM-1, P-selectin, soluble TNF receptor-1, and CXC chemokine ligand 16 in multiple murine lupus strains and human lupus nephritis. J Immunol 2007, 179:7166-7175.
10. Ikeda Y, Fujimoto T, Ameno M, Shiiki H, Dohi K. Relationship between lupus nephritis activity and the serum level of soluble VCAM-1. Lupus 1998, 7:347-354. 10.1191/096120398678920172, 9696139.
11. Ilic T, Mitic I, Durdevic-Mirkovic T, Vuckovic B, Milic B, Popovic M. Correlation between sera levels of sICAM-1 and sVCAM-1 and severity of kidney lesions in patients with lupus nephritis. Med Pregl 2007, 60(Suppl 2):128-132.
12. Wada T, Yokoyama H, Su SB, Mukaida N, Iwano M, Dohi K, Takahashi Y, Sasaki T, Furuichi K, Segawa C, Hisada Y, Ohta S, Takasawa K, Kobayashi K, Matsushima K. Monitoring urinary levels of monocyte chemotactic and activating factor reflects disease activity of lupus nephritis. Kidney Int 1996, 49:761-767. 10.1038/ki.1996.105, 8648917.
13. Molad Y, Miroshnik E, Sulkes J, Pitlik S, Weinberger A, Monselise Y. Urinary soluble VCAM-1 in systemic lupus erythematosus: a clinical marker for monitoring disease activity and damage. Clin Exp Rheumatol 2002, 20:403-406.
14. Noris M, Bernasconi S, Casiraghi F, Sozzani S, Gotti E, Remuzzi G, Mantovani A. Monocyte chemoattractant protein-1 is excreted in excessive amounts in the urine of patients with lupus nephritis. Lab Invest 1995, 73:804-809.
15. Rovin BH, Birmingham DJ, Nagaraja HN, Yu CY, Hebert LA. Biomarker discovery in human SLE nephritis. Bull NYU Hosp Jt Dis 2007, 65:187-193.
16. Tesch GH, Maifert S, Schwarting A, Rollins BJ, Kelley VR. Monocyte chemoattractant protein 1-dependent leukocytic infiltrates are responsible for autoimmune disease in MRL-Fas(lpr) mice. J Exp Med 1999, 190:1813-1824. 10.1084/jem.190.12.1813, 2195716, 10601356.
17. Marks SD, Williams SJ, Tullus K, Sebire NJ. Glomerular expression of monocyte chemoattractant protein-1 is predictive of poor renal prognosis in pediatric lupus nephritis. Nephrol Dial Transplant 2008, 23:3521-3526. 10.1093/ndt/gfn270, 18495743.
18. Wuthrich RP. Vascular cell adhesion molecule-1 (VCAM-1) expression in murine lupus nephritis. Kidney Int 1992, 42:903-914. 10.1038/ki.1992.367, 1280699.
19. Zhu J, Liu X, Xie C, Yan M, Yu Y, Sobel ES, Wakeland EK, Mohan C. T cell hyperactivity in lupus as a consequence of hyperstimulatory antigen-presenting cells. J Clin Invest 2005, 115:1869-1878. 10.1172/JCI23049, 1143586, 15951839.
20. Pizarro S, Monarrez Espino J, Ruiz A, Jara LJ, Nava A, Riebeling-Navarro C. Soluble vascular cell adhesion molecule-1 indicates SLE disease activity and specific organ involvement. Rev Alerg Mex 2007, 54:189-195.
21. Spronk PE, Bootsma H, Huitema MG, Limburg PC, Kallenberg CG. Levels of soluble VCAM-1, soluble ICAM-1, and soluble E-selectin during disease exacerbations in patients with systemic lupus erythematosus (SLE); a long term prospective study. Clin Exp Immunol 1994, 97:439-444. 1534867, 7521807.
22. Teramoto K, Negoro N, Kitamoto K, Iwai T, Iwao H, Okamura M, Miura K. Microarray analysis of glomerular gene expression in murine lupus nephritis. J Pharmacol Sci 2008, 106:56-67. 10.1254/jphs.FP0071337, 18187931.
23. Petri M, Magder L. Classification criteria for systemic lupus erythematosus: a review. Lupus 2004, 13:829-837. 10.1191/0961203304lu2019oa, 15580978.
24. Weening JJ, D'Agati VD, Schwartz MM, Seshan SV, Alpers CE, Appel GB, Balow JE, Bruijn JA, Cook T, Ferrario F, Fogo AB, Ginzler EM, Hebert L, Hill G, Hill P, Jennette JC, Kong NC, Lesavre P, Lockshin M, Looi LM, Makino H, Moura LA, Nagata M. The classification of glomerulonephritis in systemic lupus erythematosus revisited. J Am Soc Nephrol 2004, 15:241-250. 10.1097/01.ASN.0000108969.21691.5D, 14747370.
25. Austin HA, Muenz LR, Joyce KM, Antonovych TT, Balow JE. Diffuse proliferative lupus nephritis: identification of specific pathologic features affecting renal outcome. Kidney Int 1984, 25:689-695. 10.1038/ki.1984.75, 6482173.
26. Singh S, Saxena R. Lupus nephritis. Am J Med Sci 2009, 337:451-460. 10.1097/MAJ.0b013e3181907b3d, 19390431.
27. Houssiau FA. Management of lupus nephritis: an update. J Am Soc Nephrol 2004, 15:2694-2704. 10.1097/01.ASN.0000140218.77174.0A, 15466274.
28. Cameron JS. Lupus nephritis. J Am Soc Nephrol 1999, 10:413-424.
29. Font J, Torras A, Cervera R, Darnell A, Revert L, Ingelmo M. Silent renal disease in systemic lupus erythematosus. Clin Nephrol 1987, 27:283-288.
30. Zabaleta-Lanz M, Vargas-Arenas RE, Tapanes F, Daboin I, Atahualpa Pinto J, Bianco NE. Silent nephritis in systemic lupus erythematosus. Lupus 2003, 12:26-30. 10.1191/0961203303lu259oa, 12587823.
31. Wada Y, Ito S, Ueno M, Nakano M, Arakawa M, Gejyo F. Renal outcome and predictors of clinical renal involvement in patients with silent lupus nephritis. Nephron Clin Pract 2004, 98:c105-c111. 10.1159/000081551, 15627787.
32. Bajaj S, Albert L, Gladman DD, Urowitz MB, Hallett DC, Ritchie S. Serial renal biopsy in systemic lupus erythematosus. J Rheumatol 2000, 27:2822-2826.
33. Arrizabalaga P, Sole M, Iglesias C, Escaramis G, Ascaso C. Renal expression of ICAM-1 and VCAM-1 in ANCA-associated glomerulonephritis - are there differences among serologic subgroups?. Clin Nephrol 2006, 65:79-86.
34. Abd-Elkareem MI, Al Tamimy HM, Khamis OA, Abdellatif SS, Hussein MR. Increased urinary levels of the leukocyte adhesion molecules ICAM-1 and VCAM-1 in human lupus nephritis with advanced renal histological changes: preliminary findings. Clin Exp Nephrol 2010, 14:548-557. 10.1007/s10157-010-0322-z, 20714774.
35. Zhang Q, Zeng C, Fu Y, Cheng Z, Zhang J, Liu Z. Biomarkers of endothelial dysfunction in patients with primary focal segmental glomerulosclerosis. Nephrology (Carlton) 2012, 17:338-345.
36. Honkanen E, von Willebrand E, Teppo AM, Tornroth T, Gronhagen-Riska C. Adhesion molecules and urinary tumor necrosis factor-alpha in idiopathic membranous glomerulonephritis. Kidney Int 1998, 53:909-917.
37. Saxena V, Lienesch DW, Zhou M, Bommireddy R, Azhar M, Doetschman T, Singh RR. Dual roles of immunoregulatory cytokine TGF-β in the pathogenesis of autoimmunity-mediated organ damage. J Immunol 2008, 180:1903-1912. 2291535, 18209088.